유럽의 유전체 시퀀싱 시장 : 제품, 최종사용자, 국가별 분석과 예측(2024-2033년)

Introduction to Europe Genome Sequencing Market

The Europe genome sequencing market was valued at $2.22 billion in 2024 and is expected to reach $7.23 billion by 2033, growing at a CAGR of 14.04% between 2024 and 2033. Through the process of identifying the entire sequence of an organism's DNA, genome sequencing allows scientists to decipher its entire genetic composition. This process helps identify genetic variations and their potential impact on health and disease. The genome sequencing market in Europe is expanding due to factors such as the decreasing cost of sequencing, increasing adoption of genome testing, and the growing demand for prenatal and newborn screening programs that leverage next-generation sequencing technologies.

The expanding applications of long-read sequencing, which provide more detailed and accurate insights into complex genetic information, further drive market growth. In addition, government investments and initiatives in genome sequencing projects across Europe have significantly boosted accessibility and adoption.

As the area keeps its attention on developments in healthcare and precision medicine, genome sequencing is becoming a critical tool for improving diagnostics, personalized treatments, and disease prevention. These trends are set to shape the future of the genome sequencing market in Europe, ensuring continued innovation and wider consumer access.

Market Introduction

The growing demand for genetic testing, the growing use of precision medicine, and improvements in sequencing technologies are all contributing to the notable growth of the European genome sequencing market. An increasingly important tool in research, diagnostics, and individualized healthcare is genome sequencing, which decodes an organism's entire DNA sequence.

As next-generation sequencing (NGS) becomes more widely available and sequencing costs decline, the technology becomes more accessible, facilitating its integration into European healthcare systems. Prenatal and neonatal screening, cancer diagnosis, rare disease detection, and pharmacogenomics are important uses.

The market is being further stimulated by government programs and investments in genomic research projects, such as the UK's 100,000 Genomes Project. More precise and thorough genetic analysis is now possible thanks to the growing use of long-read sequencing technologies, improving clinical outcomes.

As Europe continues to prioritize innovation in healthcare, the genome sequencing market is set to play a pivotal role in advancing medical research and delivering personalized treatments.

Market Segmentation

Segmentation 1: by Product

• Kits
• Instruments
• Software

Segmentation 2: by End User

• Pharmaceutical and Biotechnology Companies
• Hospitals and Diagnostic Laboratories
• Population Sequencing Organizations
• Research and Academic Institutes
• Others

Segmentation 3: by Region

• Europe
  • Germany
  • U.K.
  • Spain
  • Italy
  • France
  • Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The Europe genome sequencing market has been segmented based on various categories, such as by product, end user, and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe genome sequencing market is a highly fragmented market, with many public and few private companies. Key players in the genome sequencing market analyzed and profiled in the study involve established players that offer various kinds of products.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Eurofins Scientific S.E.
• F. Hoffmann-La Roche Ltd.
• OncoDNA
• Oxford Nanopore Technologies plc
• QIAGEN N.V.

Table of Contents

Executive Summary

Scope and Definition

1 Europe Genome Sequencing Market: Industry Analysis

• 1.1 Key Trends: Current and Future Impact Assessment
  • 1.1.1 Integration of Artificial Intelligence and Machine Learning in Genome Sequencing
  • 1.1.2 Increasing Partnerships, Alliances, and Business Expansions among Key Players
• 1.2 Regulatory Analysis
• 1.3 Value and Supply Chain Analysis

2 Europe Genome Sequencing Market: Future Outlook

• 2.1 Patent Analysis
  • 2.1.1 Patent Analysis (by Year)
  • 2.1.2 Patent Analysis (by Country)
• 2.2 Competitive Benchmarking
  • 2.2.1 Market Share
  • 2.2.2 Brand Recognition
• 2.3 Sequencing Clinical Adoption
• 2.4 Future Outlook

3 Genome Sequencing Market (By Region)

• 3.1 Regional Summary
• 3.2 Drivers and Restraints
• 3.3 Europe
  • 3.3.1 Regional Overview
  • 3.3.2 Driving Factors for Market Growth
  • 3.3.3 Factors Challenging the Market
  • 3.3.4 By Product
  • 3.3.5 By End User
  • 3.3.6 Germany
    • 3.3.6.1 By Product
  • 3.3.7 U.K.
    • 3.3.7.1 By Product
  • 3.3.8 Spain
    • 3.3.8.1 By Product
  • 3.3.9 Italy
    • 3.3.9.1 By Product
  • 3.3.10 France
    • 3.3.10.1 By Product
  • 3.3.11 Rest-of-Europe
    • 3.3.11.1 By Product

4 Genome Sequencing Market - Competitive Benchmarking and Company Profiles

• 4.1 Key Strategies and Development
  • 4.1.1 Partnerships, Alliances, and Business Expansions
  • 4.1.2 Regulatory and Legal Activities
  • 4.1.3 New Offerings
  • 4.1.4 Mergers and Acquisitions
  • 4.1.5 Funding Activities
• 4.2 Company Profiles
  • 4.2.1 Eurofins Scientific S.E.
    • 4.2.1.1 Overview
    • 4.2.1.2 Top Products and Services
    • 4.2.1.3 Top Competitors
    • 4.2.1.4 Key Personnel
    • 4.2.1.5 Analyst View
  • 4.2.2 F. Hoffmann-La Roche Ltd.
    • 4.2.2.1 Overview
    • 4.2.2.2 Top Products and Services
    • 4.2.2.3 Top Competitors
    • 4.2.2.4 Key Personnel
    • 4.2.2.5 Analyst View
  • 4.2.3 OncoDNA
    • 4.2.3.1 Overview
    • 4.2.3.2 Top Products and Services
    • 4.2.3.3 Top Competitors
    • 4.2.3.4 Key Personnel
    • 4.2.3.5 Analyst View
  • 4.2.4 Oxford Nanopore Technologies plc
    • 4.2.4.1 Overview
    • 4.2.4.2 Top Products and Services
    • 4.2.4.3 Top Competitors
    • 4.2.4.4 Key Personnel
    • 4.2.4.5 Analyst View
  • 4.2.5 QIAGEN N.V.
    • 4.2.5.1 Overview
    • 4.2.5.2 Top Products and Services
    • 4.2.5.3 Top Competitors
    • 4.2.5.4 Key Personnel
    • 4.2.5.5 Analyst View

5 Research Methodology

• 5.1 Data Sources
  • 5.1.1 Primary Data Sources
  • 5.1.2 Secondary Data Sources
  • 5.1.3 Data Triangulation